Publication:


abstract

The European Medicines Agency has recently approved the Use of telaprevir (Incivo®, Janssen) and boceprevir (Victrelis®, MSD) combined with pegylated interferon and ribavirin in triple therapy as the treatment of choice in patients with genotype 1 chronic hepatitis C infection. The high efficacy of triple therapy, even in patients with cirrhosis or those previously unresponsive to pegylated interferon and ribavirin, represents a major step forward in the management of chronic hepatitis C infection. However, in routine clinical practice, triple therapy poses a major challenge requiring detailed knowledge of various aspects that differ substantially from the standard therapy of hepatitis C infection with pegylated interferon and ribavirin. These aspects include the profile and management of the most common adverse effects, the most important drug interactions, and the importance of respecting the guidelines for treatment withdrawal.

Copyright © 2011 Elsevier España, S.L. and AEEH y AEG. All rights reserved.

Related Articles
Review [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Orv Hetil. 2011
Review [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B, Kovács B, Battyáni Z. Orv Hetil. 2011 Dec 11; 152(50):1997-2009.
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
Swiss Med Wkly. 2012
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
Swiss Association for the Study of the Liver. Swiss Med Wkly. 2012 Feb 24; 142:w13516. Epub 2012 Feb 24.
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
J Manag Care Pharm. 2011
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Tungol A, Rademacher K, Schafer JA. J Manag Care Pharm. 2011 Nov; 17(9):685-94.
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
J Viral Hepat. 2012
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. J Viral Hepat. 2012 May; 19 Suppl 2:1-26.
Review Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Health Technol Assess. 2004
Review Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Health Technol Assess. 2004 Oct; 8(39):iii-iv, 1-125.